Digital tools, multidisciplinarity and innovation for communicating vaccine safety in the COVID-19 eraArticle Published on 2022-12-312023-07-06 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), [키워드] human-centered design infodemic Innovation social media listening Vaccine communication vaccine safety vaccine safety net. [DOI] 10.1080/21645515.2020.1865048 PMC 바로가기
A Narrative Review of Innovative Responses During the COVID-19 Pandemic in 2020Review Published on 2022-12-082023-07-11 Journal: International Journal of Public Health [Category] COVID19(2023년), [키워드] COVID-19 Frugal innovation Healthcare system Innovation process innovation repurposing technological innovation. [DOI] 10.3389/ijph.2022.1604652 PMC 바로가기 [Article Type] Review
Transmission of SARS-CoV-2 by children to contacts in schools and households: a prospective cohort and environmental sampling study in LondonArticle Published on 2022-11-012022-11-16 Journal: The Lancet. Microbe [Category] SARS, 변종, 치료기술, [키워드] acquisition Assessing Asymptomatic children Community Contact Contamination Department eight Evidence FIVE Frequency Genome sequencing Health household contact household contacts IMPROVE incident index case Infection Innovation Laboratory Local London occur PCR testing positive positive PCR positive SARS-CoV-2 PCR Precaution Prevent prospective cohort public health pupil Pupils quantified reduced representing rising SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 transmission School Schools secondary transmission Spread supported symptomatic individual tested Testing throat swab Transmission transmission of SARS-CoV-2 variant Ventilation viral shedding was done Weekly with COVID-19 [DOI] 10.1016/S2666-5247(22)00124-0 PMC 바로가기
Pandemic driven innovation: A pilot evaluation of an alternative respiratory pathogen collection deviceArticle Published on 2022-11-012022-11-16 Journal: The American journal of emergency medicine [Category] SARS, 유전자 메커니즘, [키워드] absence All participant amplification communicable disease COVID-19 demonstrated determine diagnostic enrolled evaluated faster favor feedback fused gold standard identify inhibitor Innovation Interpretation invasive mechanism nasopharyngeal Nasopharyngeal swab nucleic acids participant Patient PCR PCR cycle PCR testing pilot study polymerase chain positive producing real-time reverse transcriptase receiving respiratory respiratory pathogen respiratory virus Result resulting RNase P RNAseP RT-qPCR Self-collection respiratory pathogen device. specimen study participant TaqPath tested threshold [DOI] 10.1016/j.ajem.2022.08.047 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses analysis Analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
Effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control for hospital-onset COVID-19 infection: Multicentre, prospective studyArticle Published on 2022-09-132022-11-15 Journal: eLife [Category] SARS, 진단, 치료기술, [키워드] 95% CI Admission baseline Capacity changed clinical COG-UK collected conducted COVID-19 COVID-19 infection detect Epidemiology evaluated Evidence extreme global health HAI Health Service Healthcare-associated infection hospital Hospital-acquired infection Human incidence incidence rate Infection infection control Infection prevention Infectious disease Innovation Intervention knowledge Limited Medical Research Council Microbiology molecular Molecular epidemiology MRC NIHR non-randomised trial nosocomial outbreak per-protocol Prospective Study resources respond returned SARS-CoV-2 SARS-CoV-2 genome sequencing sensitivity analysis sequence Sequencing Site statistically significant supported Transmission Trial viral genomics. Volume Wellcome Sanger Institute were recorded while [DOI] 10.7554/eLife.78427 PMC 바로가기
Innovation in crisis: The role of ‘exaptive relations’ for medical device development in response to COVID-19Research article Published on 2022-09-012022-10-05 Journal: Technological Forecasting and Social Change [Category] 신약개발, 유전자 메커니즘, 진단, [키워드] addition Collaborative effort contribute COVID-19 COVID-19 pandemic Critical debatable Drawing events Exaptation healthcare Innovation Medical innovation organization subject [DOI] 10.1016/j.techfore.2022.121863 [Article Type] Research article
Covid-19, an unfinished storyMini review Published on 2022-09-012022-10-05 Journal: La Presse Médicale [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] activities acute respiratory distress age amplitude bat coronavirus Beta Betacoronavirus caused China Cluster Comorbidities compulsory vaccination condition confirmed case coronavirus COVID-19 Critical cross deaths degree Delta detect development drug effective Efficacy epidemic waves epidemiological surveillance evade Face mask FIVE form Gamma Genome genomic Health highly pathogenic homogeneity Host Human immune response Immunity incidence rate include Inflammatory Innovation intensive care Measures Messenger RNA mild infection Moderna mRNA vaccine multiorgan failure nucleotides occupancy rate omicron Oxygen therapy pandemic Patient Pfizer-BioNTech Pneumonia preventing the transmission progressed Protective replaced RNA SARS-CoV-2 SARS-CoV-2 vaccine Sequencing severity syndrome the WHO thromboembolic complications Vaccine Vaccines variant variants variants of concern viral invasion VoC WHO World Health Organization [DOI] 10.1016/j.lpm.2022.104131 [Article Type] Mini review
A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial – implications for therapeutic immune modulationResearch article Published on 2022-08-182022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, 변종, 임상, [키워드] 1:1 Activation Adaptive immune response addition adverse event ARCADIA assigned AZD1656 Clinical improvement clinical trial Complete COVID-19 cytokine Czech Republic Day death decrease diabetes diabetic patient diabetic patients dose double-blind duration of hospitalisation Efficacy Excalibur False positive finding Full Analysis Set funding Glucokinase activator group homeostatic hospital hospital discharge hospitalised identify immune Immune cell immune modulation immune response Immunochemistry immunomodulatory effect Immunophenotyping implication indicated Innovation investigated involved less Medicine multicentre nine no difference Patient phase Phase 2 Placebo placebo-controlled placebo-controlled clinical trial primary analysis primary endpoint pro-inflammatory randomised Randomly receive recruited reduction in Registered regulatory T cells required risk Romania SARS-CoV-2 screened statistically significant difference suggested Tablet the placebo group therapeutic therapeutic effect treated Treatment treatment allocation Tregs Trial usual care with COVID-19 [DOI] 10.1016/j.eclinm.2022.101604 [Article Type] Research article
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trialsClinical Trial Published on 2022-08-122022-10-05 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] adverse event Anti-RBD IgG AstraZeneca baseline Biotechnology Cellular immune response cellular immune responses clinical clinical trial Coalition conducted convalescent serum correlation COVID-19 COVID-19 vaccination COVID-19 vaccine CpG1018 Department domain doses Efficacy finding foundation funding groups humoral immune responses incidence India Innovation Melinda Gate Moderna multicentre NAb neutralising antibody observation Open-label profile Protein subunit randomised randomly divided Receptor-binding domain Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection second dose significantly Spike protein the vaccine titre titres Trial Vaccine [DOI] 10.1016/j.ebiom.2022.104217 [Article Type] Clinical Trial